AK-POLY-BAC Ophthalmic Ointment Recall for Manufacturing Compliance Deviations
Akorn, Inc. recalls all lots of AK-POLY-BAC ophthalmic ointment nationwide because the company ceased operations and could not complete required stability testing.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall with no reported illnesses or injuries. The recall is precautionary due to the manufacturer's inability to complete required stability studies, not due to confirmed contamination or harm.
Plain-English summary
AK-POLY-BAC (bacitracin Zinc and Polymyxin B Sulfate) Ophthalmic Ointment, 3.5g, manufactured by Akorn, Inc., is being recalled. The product is a sterile, prescription ointment for topical ophthalmic use. All lots and all NDC codes are affected.
The FDA has issued a recall due to current good manufacturing practice (CGMP) deviations. The manufacturer went out of business and could no longer complete the stability studies required to verify that the product maintained its sterility and potency throughout its shelf life.
The affected product was distributed nationwide in the United States and Puerto Rico.
Patients currently using this medication should contact their healthcare provider for guidance. Healthcare providers and pharmacies should discontinue dispensing AK-POLY-BAC and should inform patients who received this product of the recall.
The recalled product
- Product
- AK-POLY-BAC (bacitracin Zinc and Polymyxin B Sulfate) Ophthalmic Ointment, 3.5g, Sterile, Rx Only, For Ophthalmic Use Only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045. ALL NDCs
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Ophthalmic Antibiotic
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All Lots
Distribution
Part of a larger recall action
This product is one of 86 recalled by Akorn, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 86 products in this recall →Related recalls
Same manufacturer · Akorn, Inc.
See all →- HighTobramycin Ophthalmic Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighGuaifenesin Oral Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Calcitriol Injection Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-06-07
- HighAkorn Hydromorphone Hydrochloride Injection Recalled Due to CGMP Deviations
FDA (Drugs) · 2023-06-07
- HighMidazolam Injection Recalled Due to Manufacturing Compliance and Stability Study Issues
FDA (Drugs) · 2023-06-07
Same hazard · cgmp deviation
See all →- SevereBaxter Recalls Vasopressin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateLexia LLC Recalls Broadway Joe's Pain Cream Due to CGMP Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
Similar recalls
- HighFDA Recalls Akorn AK-POLY-BAC Eye Ointment for CGMP Violations
FDA (Drugs) · 2023-01-25
- ModerateFDA recalls Akorn ophthalmic ointment for manufacturing process deviations
FDA (Drugs) · 2023-01-25
- ModerateDrug Recall: Erythromycin Ophthalmic Ointment Due to Manufacturing Deviations
FDA (Drugs) · 2023-01-25
- ModeratePharma Pac Recalls Neomycin Ophthalmic Ointment for Quality Control Issues
FDA (Drugs) · 2019-08-07
- SevereAltaire Recalls Polycin Ophthalmic Ointment Due to Sterility Concerns
FDA (Drugs) · 2019-11-27
- SevereAkorn Recalls Gentamicin Sulfate Ophthalmic Solution Due to Impurities
FDA (Drugs) · 2019-03-20